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BACKGROUND: HPV16/18 detection may improve cervical cancer risk stratification and better guide which HPV-positive women
warrant immediate colposcopy/biopsy. We estimated risks of cervical precancer and cancer by HPV genotype and cytology during
the implementation phase of primary HPV testing in Norway.
METHODS: A total of 3111 women, aged 34–69 years, testing HPV-positive at baseline and undergoing cytology testing from
February 2015 to April 2018 had data available for analysis. Risk estimates with 95% confidence intervals (95%CIs) of cervical
intraepithelial neoplasia grade 3 or more severe (CIN3+) were estimated for cytology results and HPV genotypes (HPV16, HPV18,
and other high-risk HPV).
RESULTS: CIN3+ risks were higher for HPV16/18 than other high-risk HPV genotypes. Among women with any cytologic
abnormality [atypical squamous cells of undetermined significance or worse], immediate risks were 57.8% (95%CI= 53.0–62.6%) for
HPV16, 40.2% (95%CI= 32.3–49.2%) for HPV18, and 31.4% (95%CI= 28.7–34.3%) for other high-risk HPV. Among those with normal
cytology, CIN3+ risks were 19.9% (95%CI= 15.0–26.1%) for HPV16 positives, 10.8% (95%CI= 5.6–20.5%) for HPV18 positives, and
5.5% (95%CI= 4.2–7.1%) for other high-risk HPV.
CONCLUSIONS: The benefits and harms of managing women based on HPV positivity and cytology results can be better balanced
by inclusion of HPV genotyping in screening and choosing more conservative management for other high-risk HPV compared to
HPV16/18.
British Journal of Cancer (2020) 122:1715–1723; https://doi.org/10.1038/s41416-020-0790-1
BACKGROUND
Women with human papillomavirus (HPV) infections that persist
for at least one1 or two years2 are at high risk of cervical
precancers (cervical intraepithelial neoplasia grade 2 [CIN2], grade
3 [CIN3], adenocarcinoma in situ [AIS] and cervical cancer). HPV
infection in women over 30 years old is more likely to be
persistent, with a greater likelihood of the development of high-
grade cervical intraepithelial neoplasia (CIN2/3) or cervical cancer.3
Randomised controlled trials have demonstrated that primary
HPV screening leads to a greater reduction in the overall incidence
of cervical cancer compared to conventional cytology-based
screening and it is now recommended to use HPV as a screening
test for women over 30 years of age.4,5 HPV testing is also more
sensitive than cervical cytology alone in detecting CIN2 or more
severe diagnoses (CIN2+) and CIN3 or more severe diagnoses
(CIN3+).5–8 However, primary HPV screening also detects transient
HPV infections, which increases the number of positive screening
results and potentially the number of colposcopies performed,5,9
the latter depending on the criteria for referral to colposcopy.
Particularly for HPV-positive women with cytology negative
for intraepithelial lesion or malignancy (NILM) or low-grade
cytology, over-referral to colposcopy can lead to a larger
number of colposcopy/biopsy results negative for CIN2+.10
This presents a major challenge to the limited colposcopy
capacity in most healthcare systems.10,11 It is important to
choose a colposcopy referral threshold based on the balance
between benefits and harms.
The optimal triage protocol for HPV-positive women in routine
clinical setting is not yet determined but cytology is currently the
general standard. The risk of CIN2+ and CIN3+ varies among
oncogenic HPV genotypes.2,12–15 HPV16 and/or 18 infection are
found in 70% of cervical cancers,16 and confer a higher risk than
other high-risk HPV genotypes.17,18 Among women undergoing
primary HPV screening, partial HPV genotyping in combination
with cytology may better determine women who should be
referred to biopsy compared to cytology alone. In a large US
cohort study, women positive for HPV16 were at highest risk for
CIN3+, followed by HPV18.19 Similar results were also found in a
Japanese longitudinal study20 and a large clinical trial, ATHENA
(Addressing the Need for Advanced HPV Diagnosis).21 However,
observational studies and randomised controlled trials have
specific enrolment criteria that may limit the applicability of
results to whole populations. Such limitations include results
reflecting subgroups of populations and possible under- or over-
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estimation of outcomes due to censoring and aggressive follow-
up.21,22 Risk assessments using real-world or population-based
data is needed to ensure “equal management for equal risk”
for referral to colposcopy for populations with different patterns
of care, compliance, testing, rescreening intervals, and risk
factors.12,23 Consequently, national screening programs should
evaluate and calibrate their screening algorithms based on
accepted cervical cancer risk threshold for referring to colposcopy
and based on the population’s real-world screening data and
capacity.
The Norwegian Cervical Cancer Screening Program (NCCSP)
requires data generated within Norway using a real-world
population base to modify national screening guidelines. This
study aimed to estimate CIN3+ and CIN2+ risks by combinations
of HPV16, HPV18, and other high-risk genotypes and cytological




Women aged 34–69 years and living in four Norwegian counties
(Sør- and Nord-Trøndelag, Hordaland and Rogaland), were
pseudo-randomly assigned by birthday to undergo 5-yearly
primary HPV screening or continue to receive 3-yearly cytology
screening (even or odd day of birth, respectively), from February
2015 until April 2018.24 An exfoliated cervical specimen was
collected during pelvic examination using a routinely available
collection devices, usually a dry brush for collecting exfoliating
cells, which was then rinsed immediately after collection into a
ThinPrep (PreservCyt® Solution, Hologic, Inc., Marlborough, MA,
USA) for HPV and liquid-based cytology (LBC) testing. Vials were
then transported to one of three laboratories for pre-processing
and evaluation. All participating laboratories followed a set of
guidelines, approved by the Academic Panel for HPV screening
implementation in Norway and described in the Quality Assurance
Manual for the NCCSP, for allocation, conduction and follow-up of
both screening strategies to unify implementation routines.
Laboratory testing
HPV testing. HPV testing was conducted utilising the cobas 4800
HPV test (Roche Diagnostics, Basel, Switzerland) as previously
described.24 Briefly, the real-time polymerase chain reaction-based
method detects 14 HPV genotypes. Results are reported
separately for HPV16 and HPV18. The other 12 types (31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 66, and 68) are reported concurrently as a
pooled result referred to as other high-risk HPV.25,26
Cytology testing. For HPV-positive women, a baseline cytologi-
cal evaluation of the cervical sample was performed at T0, the
beginning of the observation period for each subject (Supple-
mentary Fig. 1). Liquid-based cytology was reported according
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Fig. 1 Flow diagram describing selection criteria of primary HPV test participants in the Norwegian Cervical Cancer Screening Program,
2015 to 2018. *HPV negatives (83,601) and those 2536 HPV positives with limited follow-up due to late testing because they had been
screened towards the end of the enrolment period. Abbreviations: NILM, negative for intraepithelial lesion or malignancy; ASC-US, atypical
squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesions, AGC, atypical glandular cells; ASC-H, atypical
squamous cells, cannot rule out high-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesions; ACIS; atypical
glandular cells cervical adenocarcinoma in situ; SCC, squamous cell carcinoma.
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to the Bethesda system27 as unsatisfactory, NILM, atypical
squamous cells of undetermined significance (ASC-US), low-
grade squamous intraepithelial lesion (LSIL), atypical glandular
cells of undetermined significance (AGC), atypical squamous
cells-cannot exclude HSIL (ASC-H), high-grade squamous
intraepithelial lesion (HSIL), adenocarcinoma in situ (AIS) and
cervical carcinoma. If the cytology result was ASC-US or more
severe interpretation, “immediate” colposcopy and biopsy were
recommended.
If the baseline cytology test was NILM, then a 12-month
follow-up period was recommended prior to repeating the HPV
testing. If the repeat HPV test was positive, women were referred
for colposcopy with biopsy. If the repeat HPV test was negative,
then women return to routine screening and scheduled to be re-
screened by HPV testing in 5 years.28
A unique identification number, allowing identification of
every legal resident in Norway, was used to link the information
on cytology, HPV tests and histology at an individual level.
Relevant screening results were extracted from the databases at
the Cancer Registry of Norway for 92,076 women aged 34–69
years who underwent primary HPV screening with no recorded
abnormal HPV-tests, cytology or histology (CIN2+) the last two
years before the baseline screening test (Fig. 1). A total of 5866
(6.4%) were HPV positive, although 2536 had been excluded due
to late testing because they had been screened towards the end
of the enrolment period. Exclusions were applied to women with
unsatisfactory HPV test results with no repeat HPV test, HPV-
negative results, and women with no histological confirmation.
HPV negative women were excluded mainly because they
require 5 years of follow up and the randomised implementation
of HPV primary screening began in 2015. A total of 3111 HPV-
positive women had complete data available for analysis that
met NCCSP guidelines.
Use of Norwegian Cancer Registry data for identification and
follow-up of study subjects
The Cancer Registry of Norway receives reports of cancer and
precancerous lesions with compulsory central registration of
cervical cytology, histology, and all HPV test results (both positive
and negative), as previously described.29–31 Histological diagnoses
endpoints were CIN2+ and CIN3+ according to WHO guidelines.32
Statistical analysis
Follow-up started at the date of the baseline cytology test and
continued for all women until the worst histologically confirmed
lesion was identified. All other observations were censored after
the end of recommended follow up (9 months for HPV-positive
and ASC-US or worse results or 21 months for HPV-positive and
NILM results), which was according to NCCSP guidelines
(Supplementary Fig. 1).
Cytology results of AGC, ASC-H, HSIL, AIS and cervical carcinoma
were combined into a single “high-grade” category and LSIL and
ASC-US were combined into a single “low-grade” category. HPV
genotype results were categorised hierarchically according to
cancer risk from highest to lowest risk: HPV16 > HPV18 > other
high-risk HPV.33–36
Given that cervical carcinoma has a low incidence in Norway
and the primary goal of cervical screening is to prevent invasive
cancer, we used CIN3+ risk as our primary endpoint. We
emphasised results for CIN3+ risk rather than CIN2+ because
CIN2 is unreliably determined by pathologists37,38 and often
regresses.39,40
CIN3+ and CIN2+ risks with 95% confidence intervals (95%CI)
for each screening HPV genotype/cytology result combination
were estimated using the Kaplan–Meier failure function.41 Risks of
CIN2+ and CIN3+ were estimated among women with HPV-
positive and ASC-US+ at 9 months and among women with HPV-
positive and NILM at 21 months i.e. the baseline CIN3+ (T0) for
those referred immediately to colposcopy and the subsequent
CIN3+ risk for those undergoing follow-up HPV testing for a
second time after 12 months, as per NCCSP. In the follow-up after
12 months, 222 (17%) out of 1278 HPV-positive and NILM women
did not come to the second round of screening. We also
compared risks for younger (35–43 years) and older (44–69 years)
women stratified by the median age of the screened women,
using the log-rank test of equality for failure functions to test for
significant differences by age.42 All statistical analyses were done
using STATA statistical software: release 15 (College Station, TX:
StataCorp LLC).
Table 1. Primary HPV test by cervical cytology and age group.
Total (%) 34–43 years 44–69 years
HPV positivea
Totala 3111 100 1507 1604
No cytology or
unsatisfactory
229 7.4 120 109
NILM 1278 41.1 545 733
Had repeat HPV testb 626 49.0b 262 364
ASC-US 717 23.0 329 388
LSIL 333 10.7 190 143
High-gradec 554 17.8 323 231
HPV 16
Total 650 100 365 285
No cytology or
unsatisfactory
49 7.5 25 24
NILM 201 30.9 99 102
Had repeat HPV testb 116 57.7b 63 53
ASC-US 132 20.3 67 65
LSIL 79 12.2 55 24
High-gradec 189 29.1 119 70
HPV 18
Total 221 100 119 102
No cytology or
unsatisfactory
20 9.0 13 7
NILM 74 33.5 33 41
Had repeat HPV testb 43 58.1b 19 24
ASC-US 53 24.0 29 24
LSIL 22 10.0 11 11
High-gradec 52 23.5 33 19
HPV other high riskd
Total 2148 100 975 1173
No cytology or
unsatisfactory
150 7.0 77 73
NILM 981 45.7 403 578
Had repeat HPV testb 456 46.5b 174 282
ASC-US 498 23.2 214 284
LSIL 225 10.5 120 105
High-gradec 294 13.7 161 133
CIN cervical intraepithelial neoplasia, NILM negative for intraepithelial
lesion or malignancy, ASC-US atypical squamous cells of undetermined
significance, LSIL low grade squamous intraepithelial lesions.
aTotal includes 92 (3.0%) women who were not genotyped.
bPercentage is calculated as percent of those with NILM test who were
positive upon repeat HPV test.
cIncludes AGC, ASC-H, HSIL, and cancer.
dIncludes HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
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Table 2. Risk of CIN3+ and CIN2+ among HPV-positive women by ≥ASC-US cytology and HPV genotype.
CIN3+ CIN 2+
Total N (cases) Risk 95%CI N (cases) Risk 95%CI
All HPV positivea
ASC-US 717 154 21.5 18.7 24.7 223 31.1 27.9 34.6
LSIL 333 99 29.7 25.2 35.0 146 43.8 38.7 49.4
High-gradeb 554 359 64.8 60.9 68.8 397 71.7 67.9 75.4
≥ASC-US 1604 612 38.2 35.8 40.6 766 47.8 45.3 50.2
HPV16
ASC-US 132 51 38.6 30.9 47.5 63 47.7 39.6 56.6
LSIL 79 37 46.8 36.6 58.4 49 62.0 51.5 72.6
High-grade 189 143 75.7 69.4 81.5 153 81.0 75.1 86.2
≥ASC-US 400 231 57.8 53.0 62.6 265 66.3 61.6 70.9
HPV18
ASC-US 53 11 20.8 12.1 34.3 18 34.0 22.9 48.4
LSIL 22 6 27.3 13.3 50.9 11 50.0 31.6 71.8
High-grade 52 34 65.4 52.6 77.9 38 73.1 60.7 84.2
≥ASC-US 127 51 40.2 32.3 49.2 67 52.8 44.4 61.6
Other high-risk HPVc
ASC-US 498 90 18.1 15.0 21.7 138 27.7 24.0 31.9
LSIL 225 55 24.4 19.4 30.6 84 37.3 31.4 44.0
High-grade 294 174 59.2 53.6 64.8 198 67.4 62.0 72.6
≥ASC-US 1017 319 31.4 28.7 34.3 420 41.3 38.4 44.4
CIN cervical intraepithelial neoplasia, CI confidence interval, ASC-US atypical squamous cells of undetermined significance, LSIL low grade squamous
intraepithelial lesions.
aIncludes all HPV-positive persons with ≥ ASC-US cytology, including 60 not HPV genotyped.
bHigh grade includes AGC, ASC-H, HSIL, and cancer.
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Fig. 2 Risk of CIN3+ by low-grade and high-grade cytology for 34–43 and 44–69 years old women by HPV genotype. (a) HPV16 genotype,
(b) HPV18 genotype, (c) other high-risk HPV genotype. High grade: AGC, ASC-H, HSIL, ACIS, and SCC; Low grade: ASC-US and LSIL; Other high-
risk HPV genotype includes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68. Abbreviations: ASC-US, atypical squamous cells of undetermined
significance; LSIL, low-grade squamous intraepithelial lesions, AGC, atypical glandular cells; ASC-H, atypical squamous cells, cannot rule out
high-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesions; ACIS; atypical glandular cells Cervical
adenocarcinoma in situ; SCC, squamous cell carcinoma.
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HPV genotype and cytology counts are given for all HPV-positive
women, overall and stratified by median age (Table 1). Categoris-
ing HPV-positive women hierarchically based on genotype, 650
(20.8%) women were HPV16 positive, 221 (7.1%) were HPV18
positive, and 2148 (69.0%) were positive for other high-risk HPV;
and 92 (3.0%) for whom no HPV genotype details were recorded;
these were included in the overall HPV positive category. There
was an increasing percentage of HPV-positive women with high-
grade cytology with increasing cancer risk allocated to the
individual HPV genotype (Ptrend < 0.001). Older women were more
likely to have a NILM cytology than younger women (P < 0.001).
The overall cumulative CIN3+ risk after testing HPV-positive,
regardless of cytologic interpretation or HPV genotype, was
23.9% (95%CI= 22.7–24.3%; n= 745) and CIN2+ risk was 30.0%
(95%CI= 30.1–33.4%; n= 964) (data not shown).
Risks among HPV-positive women referred immediately to
colposcopy (ASC-US or worse cytology)
The CIN3+ risk for HPV-positive women with any abnormal
cytology, ASC-US or more severe (≥ASC-US) cytology was 38.2%
(95%CI= 35.8–40.6%).
CIN3+ and CIN2+ risks for pairwise combinations of HPV and
≥ASC-US categories are shown in Table 2. Women with HPV16-
positive high-grade cytology were at the highest risk of CIN3+
(75.7%, 95%CI= 69.4–81.5%) and CIN2+ (81.0%, 95%CI=
75.1–86.2%). By comparison, women with other high-risk HPV-
positive ASC-US cytology were at the lowest risk of CIN3+ (18.1%,
95%CI= 15.0–21.7%) and CIN2+ (27.7%, 95%CI= 24.0–31.9%).
Stratified on the median screening age of 44 years (IQR: 38–52
years), overall CIN3+ risk was higher for younger women (34–43
years) (30.6%; 95%CI= 28.3–33.2%; n= 457) compared to older
women (44–69 years) (18.1%; 95%CI= 16.3–20.9%; n= 288) (P <
0.001). Figure 2 show risks of CIN3+ for HPV genotype and high-
grade versus low-grade cytology. Within each age group, higher
risk HPV and more severe cytologic categories independently
increased the CIN3+ risk. Younger women were at higher CIN3+
risk than older women but the differences were only significant for
all HPV-positive ASC-US (27.7%, vs. 16.2%, P < 0.001) and HPV16-
positive ASC-US (47.8%, vs 29.2%, P= 0.02) and LSIL (35.2%, vs.
26.1%, P= 0.01) (data not shown).
Risks among HPV-positive women with NILM cytology
Women positive for HPV16/18 with NILM cytology had higher
CIN3+ risk compared to women positive for other high-risk HPV
with NILM cytology. CIN3+ risk by HPV genotype for NILM were
19.9% (95%CI = 15.0–26.1%) for HPV16, 10.8% (95%CI = 5.6–
20.5%) for HPV18 and 5.5% (95%CI = 4.2–7.1%) for other high-risk
HPV (Table 3).
Among those women with HPV-positive and NILM cytology
results, 626 (49.0%) re-tested HPV positive in a year. Among those
who repeatedly tested HPV-positive, most (539 of 564, 95.6%)
were positive for the same HPV genotype. Twelve-month CIN3+
risks were 29.5% (95%CI= 21.8–39.3%) among women who twice
tested HPV16 positive, 15.6% (95%CI= 6.8–33.5%) among women
who twice tested HPV18 positive, and 10.2% (95%CI= 7.7–13.6%)
among women who twice tested positive for other high-risk HPV
(Table 4). By comparison, the CIN3+ risk for twice testing high-risk
HPV positive, regardless of specific HPV results, was 14.0% (95%
CI= 11.4–17.2%).
Among women with an HPV-positive/NILM result at baseline,
those aged 34–43 years had a higher CIN3+ risk overall (11.9%; 95%
CI= 9.1–14.0%) than women aged 44–69 years (4.8%; 95%CI=
3.4–6.7%) (P < 0.001) (Figure 3 and Supplementary Table 1). By HPV
genotype, the risk between the two age groups were different for
other high-risk HPV only (P < 0.001). When stratified for age, the
results among HPV genotypes upon second HPV testing also were
only significantly different among women who were overall HPV
positive and women (P < 0.001) who were other high-risk HPV
positive (P < 0.001). All other persistent HPV genotypes had P-values
greater than 0.05 (data not shown).
DISCUSSION
For combinations of HPV-genotype and cytology results using
real-world screening data in Norway, women who tested positive
for HPV16 and/or HPV18 genotype had a higher risk of CIN3+ and
CIN2+ compared with women who tested positive for other high-
risk. This was found across every cytologic result. Women, who
tested positive for HPV16 and/or HPV18 and ≥ASC-US had a
higher risk for CIN3+ and CIN2+, and should be referred for
immediate colposcopy. The benefits and harms of managing
women based on HPV positivity and cytology results can be better
balanced by managing women with other high-risk HPV (not
HPV16 or HPV18) and low-grade cytology (ASC-US or LSIL) with
surveillance.
In Norway, cervical cancer management has been based on
results from cervical cytology primary screening.28 The switch to
the more sensitive HPV test as the primary screening test can lead
to over-referral to colposcopy, again leading to increased
likelihood of morbidity.43–45 Although an HPV positive result
alone does confer a high risk of cervical precancer and cancer
compared to a negative result, not all HPV genotypes are equally
likely to persist46 or develop into precancer or cancer.10
To increase the accuracy of the HPV screening, a cytological
evaluation of HPV positives with divergent clinical management
at threshold ASC-US+ has been recommended internationally.
Although the Bethesda classification provide criteria for cytologi-
cal definitions universally, systematic differences between
Table 3. Risk of CIN3+ and CIN2+ among HPV-positive women with NILM cytology by HPV genotype at baseline screening until regular follow-up of
21 months.
CIN3+ CIN2+
Total N (cases) Risk 95%CI N (cases) Risk 95%CI
Baseline HPV Result
HPV-positivea 1278 102 8.0 6.6 9.6 154 12.1 10.4 14.0
HPV16 201 40 19.9 15.0 26.1 49 24.4 19.0 30.9
HPV18 74 8 10.8 5.6 20.5 12 16.2 9.6 26.8
Other high-risk HPVb 981 54 5.5 4.2 7.1 92 9.4 7.7 11.4
CIN cervical intraepithelial neoplasia, CI confidence interval, NILM negative for intraepithelial lesion or malignancy.
aIncludes all HPV-positive persons with NILM cytology, including 22 not HPV genotyped.
bIncludes HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
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pathology reviewers and countries has been reported in replicat-
ing cytological results.47 These differences might explain variation
in reported proportion of those with ASC-US+ cytology (range
27–46%).48–50 Inter-laboratory differences for cytology results, are
commonly observed in Norway, suggesting further that locally
agreed diagnostic criteria and routines are applied.51 HPV testing
in screening, however, demonstrated an excellent agreement
between labs,24 suggesting wider application of molecular testing
in the follow-up. Our study demonstrate that HPV genotyping
provides further risk stratification and reduces an over-referral of
all women who have an HPV positive and low-grade or NILM
cytology result to colposcopy and biopsy.
To avoid an over-referral of all women who have an HPV
positive and low-grade or NILM cytology result to colposcopy and
biopsy, HPV genotyping provides further risk stratification.
The present analysis of HPV genotypes show consistent results
with the POBASCAM and ATHENA trials, which showed higher
precancer and cancer risk among HPV16/18 positive women
(without cytology testing).34,52,53 With cytology testing included,
the Portland-Kaiser study, a large cohort of ~20,000 women, found
that HPV16 had a 2.7 times higher risk of precancer and cancer
compared to other HPV genotypes across all cytology results.54
Among women with baseline cytology of NILM and an HPV
genotype of HPV16, 18, or other high-risk HPV type, women who
continue to test positive for the same HPV genotype upon two
screening rounds had an elevated risk compared to those with
whole sub-cohort of women with HPV-positive and NILM cytology
result at baseline. CIN3+ risk was highest for women with
persistent HPV16 positive results (30%) and lowest for persistent
other high-risk HPV-positive results (10%), indicating that the most
of the 14% CIN3+ risk for women with NILM cytology and repeat
HPV-positive test is due to persistent HPV16 infection. Similarly, an
English pilot study found that HPV 16/18 triage of persistently
high-risk HPV-positive and cytological negative women 12 months
after primary screening added very little in terms of a clinical
benefit such as additional detection of CIN2+ after baseline HPV
genotyping.55 It must be noted that, in this analysis, sample sizes
among women testing for two different HPV genotypes upon
repeat testing were small [i.e. HPV18 followed up by other high-
risk HPV positivity (n= 4)]. Thus, these findings require replication
in larger populations.
The conclusions drawn from the genotype results for the
Norwegian HPV screening implementation provide the basis for
“equal management for equal benchmark risk” approach as
performed in the US and certain European countries. This risk-
based approach12,56 uses a screening (HPV genotype and
cytology) result as a benchmark for clinical management decisions
for HPV-positive women. Based on real-world screening results
from the NCCSP, the risk threshold for a colposcopy referral
among HPV-positive women has been equivalent to the risk for
other high-risk HPV and LSIL result or ~37.3% for CIN2+ and
24.4% for CIN3+. Women above this threshold, such as those with
high-grade cytologic abnormalities or low-grade cytologic
abnormalities and test HPV16 or HPV18 positive, should immedi-
ately be referred to colposcopy and biopsy. Women with one of
these risk markers, other high-risk HPV positive with low-grade
cytologic abnormalities or test HPV16 or HPV18 positive with NILM
have a risk for CIN3+ below 24.4% and can be re-tested in
12 months. Women with neither marker, i.e., NILM cytology and
positive for other high-risk HPV, can be retested in 24 months as
they have less than half the precancer and cancer risk of women
with one of these risk markers.
This analysis focuses on immediate risks of CIN3+ by HPV
genotype, including results for women with HPV+ and NILM
cytology on their baseline test that are retested after one year. The
negative predictive value of this follow-up regimen can be
confirmed in long-term follow-up only. The relative rank order
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those HPV genotype/cytology screening results reported
elsewhere.12,56 It must also be noted that the threshold at which
the risk of cancer in an individual patient outweighs any
disadvantage of management and treatment varies according to
the patient’s characteristics and local service considerations. In a
country like Norway, with an established screening program and
with high follow-up of screen positives, the threshold for
colposcopy referral and treatment may be set higher safely, due
to the relatively low risk among women with negative test results.
Taking these factors under consideration, these results should be
interpreted as a basis for the incorporation of HPV genotyping into
primary screening as well as a rationale for risk reductions
following over-referral of women to colposcopy and biopsy after
primary HPV screening using real-world screening data.
There were several limitations. First, there was only a short follow-
up time for this cohort. Second, estimates of cervical disease (CIN2+
and CIN3+) were calculated based on women who underwent
concurrent colposcopy and biopsy. Women with an NILM cytology
and HPV-negative result are not typically referred to colposcopy and
biopsy and therefore, their cervical histology status is not known.
Women who do undergo immediate colposcopy and biopsy with an
NILM cytology result, which is against NCCSP and most other
cervical cancer screening guidelines, likely represent a biased
sample.57 It has also been shown that precancer and cancer risk
for women with an NILM cytology and HPV-positive result is 5.9%,
making the likelihood of undetected precancer and cancer in a
subset of these women quite low.49
Despite these limitations, this study has notable strengths. This
is the first study to investigate the role of HPV partial genotyping
and cytology in an HPV-based screening programme in Norway.
Norway has a population-based registration system of cytology
results and biopsies and all results are included even if women
chose to attend private healthcare. This system reduces loss to
follow-up risk and selection biases and has shown to be highly
reproducible.58 Further, data were collected uniformly, and
laboratory tests were performed within an organised cervical
cancer screening program with relatively high-population cover-
age. Results of this analysis can, therefore, be generalisable to a
larger population-based cervical screening program, which is a
prerequisite for advocating population-wide cancer screening
management by HPV genotype. While not generalisable to certain
other populations with different patterns of care, compliance,
testing, rescreening intervals, or risk factors,12 the results of this
study have altered the management protocol for HPV-positive
women living in Norway,59 providing an example of using
population-based screening data as a basis for which to
implement screening (Supplementary Fig. 2). The results obtained
are thus valuable for both Norwegian and non-Norwegian
policymakers, as well as for public health organisations that aim
to reduce cervical cancer burden.
In conclusion, we found that HPV16 and HPV18 have a higher
risk for CIN3+ and CIN2+ and partial HPV genotyping, in
combination with cytology results, can better differentiate HPV-
positive women at higher and lower risk for cervical precancer or
cancer than cytology alone. This is crucial for women who are at
too high risk for surveillance alone, such as those with HPV16/18
and low-grade cytology, while limiting unnecessary colposcopy
and biopsy for women with lower precancer or cancer risk, such as
those positive for other high-risk HPV genotypes and low-grade
cytology. These findings provided the evidence for and adoption
of the use of partial HPV genotyping for the management of HPV-
positive women aged 34–69 years in Norway.59
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Fig. 3 Risk of CIN3+ by NILM cytology stratified by genotype. (a) 34–43-year-old women (b) 44–69-year-old women. Abbreviations: NILM,
negative for intraepithelial lesion or malignancy. Other high-risk HPV includes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
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